CD8A and neoplasm: MSCs derived from compact bone (CB) have synergistic anti-tumor efficacy in combination with an immune-activating fusion protein which is associated with the activation of CD4+ and CD8+ T cells and the inhibition of Tregs in the microenvironment of a syngeneic orthotopic ovarian cancer mouse model [88, 89].